Generic Besivance Availability

Besivance is a brand name of besifloxacin ophthalmic, approved by the FDA in the following formulation(s):

BESIVANCE (besifloxacin hydrochloride - suspension/drops; ophthalmic)

  • Manufacturer: BAUSCH AND LOMB
    Approval date: May 28, 2009
    Strength(s): EQ 0.6% BASE [RLD]

Has a generic version of Besivance been approved?

No. There is currently no therapeutically equivalent version of Besivance available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Besivance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Quinolone carboxylic acid derivatives
    Patent 5,447,926
    Issued: September 5, 1995
    Inventor(s): Konno; Fujiko & Shibata; Akihiro & Matsuda; Hideaki & Asaoka; Takemitsu & Kawahara; Ryuichi & Taido; Naokata & Kuraishi; Tasdayuki & Takeda; Sunao
    Assignee(s): SS Pharmaceutical Co., Ltd.
    A quinolone carboxylic acid derivative having the following formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an aralkyl group, an ester residual group which can be hydrolyzed in living bodies, R.sup.2 is a hydrogen atom or an amino group which may be substituted by one or two lower alkyl groups, X is a hydrogen atom or a halogen atom, Y is CH.sub.2, O, S, SO, SO.sub.2, or N--R.sup.3, wherein R.sup.3 is a hydrogen atom or a lower alkyl group, and Z is an oxygen atom or two hydrogen atoms; or a salt thereof; and an antimicrobial agent comprising the same. The compound exhibits a superior antimicrobial activity, especially against gram positive microorganisms, and is thus useful for the treatments and prevention of various infectious diseases in clinics.
    Patent expiration dates:
    • April 13, 2016
      ✓ 
      Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Quinolone carboxylic acid compositions and related methods of treatment
    Patent 6,685,958
    Issued: February 3, 2004
    Inventor(s): Samir; Roy & Santosh Kumar; Chandrasekaran & Katsumi; Imamori & Takemitsu; Asaoka & Akihiro; Shibata & Masami; Takahashi & Lyle M.; Bowman
    Assignee(s): InSite Vision Incorporated SSP Co., Ltd.
    The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Patent expiration dates:
    • June 29, 2021
      ✓ 
      Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
      ✓ 
      Drug product
  • Quinolone carboxylic acid compositions and related methods of treatment
    Patent 6,699,492
    Issued: March 2, 2004
    Inventor(s): Samir; Roy & Santosh Kumar; Chandrasekaran & Katsumi; Imamori & Takemitsu; Asaoka & Akihiro; Shibata & Masami; Takahashi & Lyle M.; Bowman
    Assignee(s): InSite Vision Incorporated SSP Co., Ltd.
    The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Patent expiration dates:
    • March 31, 2019
      ✓ 
      Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
      ✓ 
      Drug product
  • Besifloxacin ophthalmic composition for the treatment or control of infection
    Patent 8,415,342
    Issued: April 9, 2013
    Assignee(s): Bausch & Lomb Incorporated
    A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.
    Patent expiration dates:
    • November 7, 2030
      ✓ 
      Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 28, 2014 - NEW CHEMICAL ENTITY

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web1)